Abstract:335 Background: Immune checkpoint inhibitors (ICIs) plus chemotherapy has become the standard first-line regimen for advanced GC/GEJC, but the efficacy still needs to be improved. Fruquintinib is an oral, highly selective VEGFR 1/2/3 inhibitor that has synergistic antitumor effects when combined with ICIs/chemotherapy. Additionally, the phase III study (NCT03223376) of fruquintinib combined with paclitaxel in second-line GC/GEJC has achieved positive topline result. Therefore, this study was aimed to evaluate the efficacy and safety of fruquintinib combined with SOX and toripalimab as a first-line therapy in GC/GEJC. Methods: In this phase Ib/II, open-label trial (NCT05024812), patients (pts) aged 18-75 years who were HER2-negative with no previous anti-tumor therapy were enrolled. The Ib phase employed a 3+3 dose escalation design, pts were treated with fruquintinib 3mg/d, po, d1-14 (dose level; DL1), 4mg/d (DL2), or 5mg/d (DL3) in combination with fixed dose of toripalimab (240mg, iv, d1), oxaliplatin (130 mg/m 2 , iv, d1) and S-1 (40-60mg based on BSA, po, d1-14) every 3 weeks. The primary objective of phase Ib was to determine the DLT in first treatment cycle defining the PR2D. Additional 64 pts were enrolled in the phase II dose expansion stage using RP2D. Primary endpoint of phase II was PFS per RECIST 1.1. Secondary endpoints included ORR, DCR, OS, DOR and safety. Results: At data cut-off (August 31, 2023), 17 pts (9 in phase Ib; 8 in phase II) with median age 65 years old had been enrolled. 59% were male, 100% had ECOG PS 1 and 35% had liver metastasis. 10/17 (59%) pts were PD-L1 CPS ≥1. No DLTs were observed at all three dose levels. Fruquintinib 5mg/d was defined as the RP2D. Of the 16 pts evaluable for tumor response, 9 pts achieved PR, 7 pts achieved SD. The ORR was 56.3% (9/16), the DCR was 100% (16/16). Pts with PD-L1 CPS <1 were more likely to achieve better responses (4PR in 6 pts, ORR-66.7%). After a median follow-up of 5.4 months, the median PFS was 9.3 (95% CI: 4.76–NA) months and OS result was not mature. Median DOR was not reached and two responders were estimated to have a response duration ≥8.0 months. Majority of TRAEs were grade 1-2, including neutrophil count decreased (64.3%), white blood cell decreased, hypoproteinemia and platelet count decreased (all were 42.9%). Grade 3 TRAEs included neutrophil count decreased (11.8%), platelet count decreased, impaired liver function, rash, pruritus and mucositis (5.9%, one patient for each). There were no treatment related deaths in the trial. Conclusions: Fruquintinib combined with SOX and toripalimab was well tolerated, with encouraging antitumor activity as first-line treatment for advanced metastatic GC/GEJC, especially in pts with CPS <1. The trial is still recruiting, more data including the potential predictive response biomarkers would be further analyzed and reported. Clinical trial information: NCT05024812 .

Phase II study of fruquintinib as second or further-line therapy for patients with advanced biliary tract cancer.

An Exploratory Study of Fruquintinib As Second-Line Treatment for Patients with Advanced or Metastatic Biliary Tract Cancer.

Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese Patients With Advanced Nonsquamous Non‒Small-Cell Lung Cancer.

OA11.03 A Randomized, Multi-Center, Double-Blind Phase II Study of Fruquintinib in Patients with Advanced Non-Small Cell Lung Cancer

Fruquintinib with Gefitinib As First-Line Therapy in Patients Carrying EGFR Mutations with Advanced Non-Small Cell Lung Cancer: a Single-Arm, Phase II Study

JCES 01.12 A Phase II Study of Fruquintinib in Combination with Gefitinib in Stage IIIb/IV NSCLC Patients Harboring EGFR Activating Mutations

Efficacy and safety of fruquintinib plus investigator's choice of chemotherapy as second-line therapy in metastatic colorectal cancer: A multicenter, single-arm phase 2 trial.

Efficacy and Safety of Fruquintinib Plus Investigator's Choice of Chemotherapy As Second-Line Therapy in Metastatic Colorectal Cancer: Updated Results of a Multicenter, Single-Arm, Phase 2 Trial.

A phase II study of fruquintinib in the first- (1L) or second-line (2L) treatment of unresectable metastatic soft tissue sarcoma.

A phase Ib/II study of fruquintinib in combination with SOX and toripalimab as first-line treatment for advanced metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJC).

Phase 1/1b trial of fruquintinib in patients with advanced solid tumors: Preliminary results of the dose expansion cohorts in refractory metastatic colorectal cancer.

Phase II Study of Fruquintinib Plus Gefitinib in Stage IIIb/IV NSCLC Patients Harboring EGFR Activating Mutations

Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study

A Phase 1b Study of VEGFR Inhibitor Fruquintinib in Patients with Pretreated Advanced Colorectal Cancer.

Efficacy and safety of fruquintinib plus mFOLFOX6/FOLFIRI as first-line therapy in advanced metastatic colorectal cancer (mCRC).

Fruquintinib combined with sintilimab as a second-line therapy for advanced gastric and gastroesophageal junction adenocarcinoma (GC/GEJC): A phase II, single-arm, prospective study.

Phase Ib/II Trial of Hepatic Arterial Infusion Chemotherapy in Combination with Fruquintinib for Refractory Unresectable Colorectal Cancer Liver Metastases.

A Phase I/Ii Trial Of Fruquintinib In Combination With Paclitaxel For Second-Line Treatment In Patients With Advanced Gastric Cancer.

P5-5 Phase 2/3 Study of Bintrafusp Alfa with Gemcitabine Plus Cisplatin As First-Line Treatment of Biliary Tract Cancer

A phase I/IIa study of cetuximab combined with fruquintinib in the previously treated RAS/BRAF wild-type metastatic colorectal cancer: Results of the CEFRU study.

Efficacy and safety of fruquintinib with nab-paclitaxel in advanced G/GEJ cancer after exposure to immune checkpoint inhibitors: A single-center prospective clinical trial.